Corcept Therapeutics stock has delivered a very large 5 year return, yet its recent valuation checks suggest the shares are not an obvious bargain at today's level.

• Over the past 5 years, Corcept Therapeutics has returned about 4.4x, which sets a high bar for any further upside to be justified by fundamentals.
• Investor focus is currently on how demand for the company’s treatments and late stage pipeline can support future revenue, while execution and clinical outcomes across those programs remain a key risk for what the stock is worth.
• Corcept Therapeutics passes only 1 of 6 valuation checks, which leans closer to expensive than to a clear bargain on broader metrics.

The issue now is whether Corcept Therapeutics' recent share price level fairly reflects the progress in its business or builds in expectations that are hard to meet.

Is Corcept Therapeutics a Bargain on Sales?

The P/S multiple suits Corcept Therapeutics because investors often focus on revenue based metrics for commercial stage biotech companies. Corcept Therapeutics currently trades on a P/S of 14.4x, compared with a Pharmaceuticals industry average of 5.0x and a peer group average of 5.8x. On simple comparisons the stock sits on a sizeable premium to both its sector and closer peers.

However, a more tailored fair P/S ratio for Corcept Therapeutics that incorporates its margins, size and risk profile is 18.0x. That is above the current 14.4x level, which implies the stock screens as undervalued against this framework even after strong recent news on Lifyorli approval and updated revenue guidance. The gap between the current and fair multiples suggests the market is applying a discount to what this model would indicate based on sales potential.

On the P/S multiple, Corcept Therapeutics stock appears undervalued relative to the fair ratio implied by its fundamentals.

The Corcept Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around Corcept Therapeutics and spell out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. These Narratives sit on the company’s Community page. Each Narrative sets up a fair value as a thesis about how Corcept Therapeutics' business could play out over time, so you can see how that view holds up as new information arrives.

Community views on Corcept Therapeutics are split, with one side leaning into the pipeline upside and the other concentrating on execution and cost risks.

Bull case: 9% undervalued

"Impending FDA decisions for relacorilant in hypercortisolism and platinum resistant ovarian cancer, alongside a European approval process, create a visible path to multiple new product launches…"

Bear case: 26% overvalued

"Net income has declined materially despite strong top line growth, with third quarter 2025 revenue rising to $207.6 million while net income fell to $19.7 million compared to $47.2 million last year…"

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Corcept Therapeutics screens as undervalued on the tailored P/S multiple, yet it scores weakly on broader valuation checks. That mix suggests the current price already reflects meaningful expectations for revenue and margins, even if the sales based model points to some upside. The key question now is whether Corcept Therapeutics can convert its pipeline and recent product approvals into durable growth without profit pressure eroding that case. The crux of the bull versus bear debate is whether execution on those programs justifies the premium P/S or whether the market is correctly cautious about the risks that come with it.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.